Interim results from the #ADAPT JR trial demonstrate that intravenous #Efgartigimod is safe, well tolerated, and pharmacodynamically active in adolescents with #AChR antibody-positive generalized myasthenia gravis (#MG). @mda.org #MDAConference
Read more: https://bit.ly/4bbT4cE
#MyastheniaGravis